DNA damage checkpoint signaling and cancer
- Prosjektnummer
- 2012028
- Ansvarlig person
- Randi Gussgard Syljuåsen
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Karrierestipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 1. Underpinning, 5. Treatment Developement
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Oncotarget 2017 Feb 14;8(7):10966-10979.
PMID: 28030798
MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features.
Oncotarget 2016 Jun 28;7(26):40297-40313.
PMID: 27248169
Hypoxia-induced alterations of G2 checkpoint regulators.
Mol Oncol 2016 May;10(5):764-73. Epub 2016 jan 8
PMID: 26791779
Simultaneous measurement of passage through the restriction point and MCM loading in single cells.
Nucleic Acids Res 2015 Dec 15;43(22):e150. Epub 2015 aug 6
PMID: 26250117
Targeting lung cancer through inhibition of checkpoint kinases.
Front Genet 2015;6():70. Epub 2015 feb 27
PMID: 25774168
PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
Radiother Oncol 2014 Feb;110(2):355-61. Epub 2014 feb 4
PMID: 24502970
Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy.
Int J Cancer 2014 Nov 1;135(9):2085-95. Epub 2014 apr 5
PMID: 24658971
The efficacy of CHK1 inhibitors is not altered by hypoxia, but is enhanced after reoxygenation.
Mol Cancer Ther 2013 May;12(5):705-16. Epub 2013 mai 1
PMID: 23635654
The radiation-induced G2 checkpoint: impact on genome stability and cancer treatment
- Disputert:
- august 2014
- Hovedveileder:
- Randi G. Syljuåsen
Novel regulators of genomic stability
- Disputert:
- oktober 2013
- Hovedveileder:
- Randi G. Syljuåsen
- Christian Naucke Prosjektdeltaker
- Grete Hasvold Postdoktorstipendiat (finansiert av denne bevilgning)
- Randi G. Syljuåsen Prosjektleder
- Viola Nahse-Kumpf Postdoktorstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport